Moffitt Cancer Center: Innovative Combination Therapy Shows Promise for Bladder Cancer Patients Unresponsive to Standard Treatment
June 07, 2024
June 07, 2024
TAMPA, Florida, June 7 (TNSres) -- Moffitt Cancer Center issued the following news release on June 6, 2024:
In a groundbreaking advance that could revolutionize bladder cancer treatment, a novel combination of cretostimogene grenadenorepvec and pembrolizumabhas shown remarkable efficacy in patients with Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer. Results from the phase 2 CORE-001 trial, published today in Nature Medicine, reveal a significant impr . . .
In a groundbreaking advance that could revolutionize bladder cancer treatment, a novel combination of cretostimogene grenadenorepvec and pembrolizumabhas shown remarkable efficacy in patients with Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer. Results from the phase 2 CORE-001 trial, published today in Nature Medicine, reveal a significant impr . . .